Background: Glycogen storage disease type III (GSD III) is caused by mutations in AGL which encodes for a single protein with two enzyme activities: oligo-1, 4-1, 4-glucantransferase (transferase) and amylo-1, 6-glucosidase. Activity of both enzymes is lost in most patients with GSD III, but in the very rare subtype IIId, transferase activity is deficient. Since the spectrum of AGL mutations is dependent on the ethnic group, we investigated the clinical and molecular characteristics in Egyptian patients with GSD III. Methods: Clinical features were examined in five Egyptian patients. AGL was sequenced and AGL haplotypes were determined. Results: Six novel AGL mutations were identified: a large deletion (c.3481-3588q1417del1525 bp), two insertions (c.1389insG and c.2368insA), two small deletions (c.2223-2224delGT and c.4041delT), and a missense mutation (p.L620P). p.L620P was found in a patient with IIId. Each mutation was located on a different AGL haplotype. Conclusions: Our results suggest that there is allelic and phenotypic heterogeneity of GSD III in Egypt. This is the second description of a large deletion in AGL. p.L620P is the second mutation found in GSD IIId.
Introduction
Glycogen storage disease type III (GSD III; MIM ࠻232400) is an autosomal recessive inherited disorder characterized by hepatomegaly, growth retardation and fasting hypoglycemia (1, 2) . GSD III is caused by a deficiency in the glycogen debranching enzyme, a key enzyme in the degradation of glycogen. The enzyme has two independent catalytic activities, oligo-1, 4-1, 4-glucantransferase (EC 2.4.1.25) (transferase) and amylo-1, 6-glucosidase (EC 3.2.1.33) (glucosidase), located on a single 160-kDa protein. Activity of both enzymes is virtually absent in affected organs. Most patients have both liver and muscle involvement (GSD IIIa), but ;15% of the patients have liver involvement only and without any muscular manifestations (GSD IIIb). Rarely, patients have been categorized with selective loss of one of two enzyme activities (3, 4) . Selective transferase deficiency is named GSD IIId. However, the molecular basis for GSD IIId has not been fully elucidated.
A gene coding human glycogen debranching enzyme (gene symbol: AGL) has been isolated and shown to be 85 kb in length and composed of 35 exons, encoding a 7.0-kb mRNA (5) . Molecular analyses of GSD III have been performed in several ethnic populations, and over 60 different AGL mutations have been reported to date in GSD III patients (Human Gene Mutation Database; http://www.hgmd.cf.ac.uk/ ac/index.php). A majority of AGL mutations have been point mutations, small deletions, insertions, or splicing mutations. However, a large deletion has been reported in the single case (6) . Since eight missense mutations have been reported in AGL (7-10), whether these are responsible for GSD III remains unclear. Only G1448R has been characterized in vitro (11) .
The spectrum of AGL mutations in GSD III depends on the ethnic group. In an ethnic group with high rate of consanguinity, prevalent mutations have been reported (12, 13) . In Egypt, the incidence of consanguineous marriages in the general population is reported to be ;29% (14) . However, three different AGL mutations have been identified in three patients from the Delta region in Egypt (15) . To investigate the 
Materials and methods

Patients
Five Egyptian GSD III patients from five families from Cairo and Alexandria, Egypt were investigated. The patients were confirmed as having deficient debranching enzyme activity in peripheral blood cells by the method of Shin (16) . This method assessed a reverse incorporation of isotope-labeled glucose into glycogen, whereby measured activity reflects primarily that of glucosidase. Because IIId has residual glucosidase activity, this method enabled us to distinguish IIId from IIIa or IIIb (2). Tissue samples from liver or muscle were unavailable for use in this study. Consanguinity was ascertained in three out of five families. The study was approved by the Local Ethics Committees and performed with the patients' and their families' informed consent.
DNA sequence analysis of AGL
Genomic DNA was isolated from peripheral blood leukocytes.
The full coding exons, their relevant exon-intron boundaries, and the 59-and 39-flanking regions of the patients' AGL were sequenced directly as described previously (17) . In brief, 11 DNA fragments to cover AGL were amplified from genomic DNA by LA-PCR. LA-PCR products were recovered and subjected to direct sequencing with internal sequencing primers. The nucleotides of AGL cDNA were numbered according to AGL isoform 1 (GenBank accession no. NM_000642).
For the detection of the large deletion around exon 27, LA-PCR was performed for 30 cycles of denaturation and annealing/extension at 948C for 30 s and 688C for 5 min, respectively. The fragments were then electrophoresed on a 0.9% agarose gel.
Point mutations that were identified in patients were verified using restriction fragment length polymorphism (RFLP) analyses. A pair of primers (listed in Table 1 ) was used for PCR, and each specific restriction endonuclease was added to digest PCR products. Restriction digests were analyzed on polyacrylamide gel.
Fifty Egyptian control subjects were examined with LA-PCR and RFLP analyses in the same manner in order to rule out the possibility that there are mere polymorphisms in controls.
Haplotype determination in AGL
A total of 30 single nucleotide polymorphisms (SNPs) in AGL were determined as described previously (18) .
RT-PCR analysis of the AGL cDNA
Total RNA was isolated from whole blood samples from patient 1 and a normal control using QIAamp RNA blood mini kits (QIAGEN, Dü sseldorf, Germany), and reverse transcribed into single strand cDNA using random hexamers and Superscript II (Invitrogen, Carlsbad, CA, USA). AGL cDNA fragments were amplified by PCR and electrophoresed on 0.9% agarose gel as described previously (19) . In addition, PCR was performed using a sense primer in exon 26 (59-CTT ACC TCA TTT TTC TTC TGG-39) and an antisense primer in exon 29 (59-CAT GTG CCA CAA TTG AAA CG-39) to examine whether aberrant spliced cDNA was detected in patient 1.
Bioinformatical analysis
Repetitive sequences, such as Alu elements were searched using RepeatMasker software by Smit AFA, Hubley R and Green P (http://repeatmasker.org). Nucleotide sequences of intron 27 in AGL were retrieved from Homo sapiens chromosome 1 genomic contig NT_032977. Alignment of amino acid sequences from various species was performed with ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/) (20) .
Results
We identified six AGL mutations in five Egyptian patients. All were novel mutations and none were found in the 50 Egyptian controls. Four patients were homozygotes and patient 2 was a compound heterozygote. None of the patients had mutations in exon 3, indicating that none were IIIb. Sequence electropherograms and RFLP analyses are shown in Figure 1 .
Patient 1 was homozygous for a large deletion involving exon 27. LA-PCR fragment encompassing exons 25-28 was shorter than that from a control (data not shown). To further narrow the location, we designed a forward primer in exon 27 and a reverse primer in exon 28 as shown in Table 1 . The LA-PCR fragment (exon 27 to exon 28) from patient 1 was shorter than that from a control ( Figure 1A) . Sequence analysis showed a deletion of 1525 bp (g.70,338,229-70,339,753 in NT_032977). One hundred and eight bp of the 39-part of exon 27 (c.3481-3588) plus 1417 bp of the 59-part of intron 27 (c.3481-3588q1417del1525 bp) was deleted, as illustrated in Figure 2 . The deletion contained 108-bp coding sequences in exon 27 and presumably caused an in-frame deletion of 36 amino acid residues. In order to examine aberrant splicing which could be caused by this deletion, RT-PCR using a pair of primers in exons 26 and 29 was performed. No PCR fragments were detected from patient 1, while the expected 516-bp fragment was obtained from a control sample (data not shown). A nucleotide homology search showed little homology between breakpoint flanking sequences. In addition, no Alu repetitive elements were found in intron 27 by the RepeatMasker software.
Sequence analysis of patient 2 showed an insertion of G at nucleotide 1389 in exon 12 (c.1389insG). Further sequencing analysis for patient 2 revealed a deletion of GT at nucleotides 2223 and 2224 in exon 18 (c.2223-2224delGT). Thus, patient 2 was a compound heterozygote for c.1389insG and c.2223-2224delGT.
Patient 3 was homozygous for a missense mutation in exon 15. Sequence analysis of patient 3 showed a T-to-C substitution at nucleotide 1859 in exon 15. This replaces leucine by proline at codon 620 (p.L620P). No mutations, except p.L620P, were found in patient 3.
Comparison of amino acid sequences among glycogen debranching enzymes from various species showed that leucine at codon 620 was well preserved during evolution, as shown in Figure 3 . In addition, leucine at codon 620 was located in the consensus sequence four in the a-amylase superfamily (21, 22) , suggesting that this amino acid is important for enzyme activity.
Patient 4 had an insertion of A at nucleotide 2368 in exon 19 (c.2368insA). Patient 5 had a deletion of T at nucleotide 4041 in exon 31 (c.4041delT). Haplotype analysis of six mutant alleles demonstrated that each mutation was located on a different AGL haplotype (Table 2) .
Clinical features and enzyme activities in patients are shown in Table 2 . All patients had hepatomegaly and deficient enzyme activity. They did not show muscle weakness, which was consistent with the previous finding that muscle weakness is usually minimal during childhood in patients with GSD IIIa (1). Of note, patient 3 had residual enzyme activity and no episodes of hypoglycemia. This may be consistent with glucose release by glucosidase not being completely absent. A liver biopsy proved accumulation of glycogen and liver enzyme activities were increased in patient 3: alanine aminotransferase (ALT) 438 IU/L (normal range: 6-50 IU/L) and aspartate aminotransferase (AST) 363 IU/L (normal range: 11-38 IU/L).
Discussion
Our genetic analysis of five Egyptian patients revealed six novel AGL mutations, including the second large deletion and p.L620P. In addition, haplotype analysis demonstrated that each mutation was located on a different AGL haplotype. These findings support the notion that heterogeneous mutations are responsible for Egyptian GSD III patients.
A large deletion in AGL was identified in patient 1. The large deletion (c.3481-3588q1417del1525 bp) results in a missing 108-bp of 39-part of exon 27, which could not alter the reading frame for amino acids, if the resulting exon 27 was spliced and combined with exon 28. However, RT-PCR did not detect any fragments from patient 1, suggesting that neither authentic nor cryptic splicing occurred and that there were no detectable AGL mRNA due to the deletion. Some of the large deletions were caused by Alu repetitive elements mediated recombination, as we described previously (23) , but this was not the case in patient 1. In this patient, no repetitive elements were identified around the junction. Since there was little homology between breakpoint flanking sequences in exon 27 and intron 27, a mechanism for this large deletion could be non-homologous end-joining, which is thought to be responsible for deletions in genetic diseases (24) (25) (26) . Very recently, another large deletion has been reported in an Egyptian patient (6) . Thus, our case is the second large deletion in AGL.
Two novel small deletions (c.2223-2224delGT and c.4041delT) and two novel insertions (c.1389insG and c.2368insA) are predicted to lead to premature termination due to a frame shift which completely abolishes enzyme activity. These premature stop codons are likely to be recognized by non-sense-mediated mRNA-decay machinery, leading to absence of AGL mRNA.
A novel missense mutation, p.L620P, was found in patient 3. The leucine at codon 620 in glycogen debranching enzymes is well preserved among various species and was located in the consensus sequence four in the a-amylase superfamily. An amino acid substitution (corresponding to amino acids in exon 15 in the human AGL) results in loss of transferase activity, but glucosidase activity remains in a IVS10q15  tt  tt  tt  tt  cc  IVS12q74  tt  cc  cc  tt  tt  IVS12-125  aa  at  tt  aa  aa  IVS12-44  aa  aa  aa  gg  gg  IVS13-70  cc  cg  cc  gg  gg  IVS14q38  gg  gg  gg  gg  gg  IVS16q8  c c  c t  t t  c c  c c  IVS18q215  cc  cg  cc  cc  cc  IVS21q124  aa  ag  gg  aa  aa  IVS22q11  aa  gg  gg  aa  gg  IVS23-121  gg  ag  aa  gg  gg  IVS23-21  aa  at  tt  aa  aa  P1067S  PP  PP  PP  PP  PP  G1115R  GG  GG  GG  GG  GG  R1253H  RR  RR  RR  RR  RR  IVS29q45  gg  ag  gg  aa  gg  IVS29q53  tt  at  tt  aa  tt  El343K  EE  EE  EE  EE  EE  IVS32-97  gg  ag  gg  aa Nucleotide numbering starts at the initiation codon.
yeast glycogen debranching enzyme (22) . Furthermore, we expressed p.L620P mutant and normal AGL proteins in COS cells transiently, and measured both glucosidase and transferase activities. The p.L620P exhibited complete loss of transferase activity, but retained glucosidase activity compared with wild type AGL (27) . Thus, p.L620P was responsible for GSD IIId in patient 3. According to the available literature, GSD IIId patients are very rare and only one mutation has been reported: a 4-bp deletion in exon 10 (28) . This deletion was probably associated with skipping of the following exon (98 bp) in the mRNA level, leading to an in-frame mutation with loss of the corresponding 34 amino acids in exon 11. However, this was not verified with in vitro expression analysis. An amino acid homology search predicted that a putative active site for enzyme activity was located in exons 6, 13, 14, and 15 (5) . Presumably, missense mutations or in-frame deletions near these exons are more likely to cause GSD IIId, but this needs to be verified by further studies. Accordingly, p.L620P is the second mutation associated with GSD IIId.
In summary, we identified six novel AGL mutations, including the second case of the large deletion in AGL and the second mutation in GSD IIId, and showed allelic and phenotypic heterogeneity in Egypt.
